Explore Flipsnack. Transform boring PDFs into engaging digital flipbooks. Share, engage, and track performance in the same platform.
From magazines to catalogs or private internal documents, you can make any page-flip publication look stunning with Flipsnack.
Check out examples from our customers. Digital magazines, zines, ebooks, booklets, flyers & more.
Pre-made templates to create stunning publications in minutes
Here are eight reasons why you should consider choosing interactive, digital flipbooks instead of boring and static PDFs. Check them out!
European Society for Animal Cell Technology ESACT Newsletter January 2014 2 challenges we are facing in a situation where animal cell technology (ACT) is well established, the companies are doing well, research is active (e.g. several CHO genomes have been published) and ESACT is not only legal but also a wealthy society. These facts suggest that nothing needs to be changed and everything could continue along established lines. We believe, however, that this is the right time to tackle some points that were raised some time ago but were always overtaken by other items, seemingly, higher priority. The first point concerns the question what ESACT is doing between the biannual meetings. In fact, for a few years now, several satellite meetings and courses have been held with ESACT support, either by direct involvement of ESACT members and/or by financial bursary support. The XC has decided to extend this type of activity and to increase the number of courses offered. In 2014, we will announce 2 courses, one on Animal Cell Technology and the second, a one, new, about „compound screening with mammalian cells“. Thanks to the continuous input from Paula Alves and Quico Gòdia and with the new activity from Christa Burger, these courses will be offered at Llafranc, close to Barcelona. In addition, a further course on Vaccine production, organized by Paula Alves in collaboration with University College London, will take place in Oeiras, Lisbon under the umbrella of ESACT. This is to say thank you to the organizers and lecturers of these courses for their extra efforts. Our support for ACT courses in Latin-America will be continued by funding travel for course lecturers from ESACT. We hope that the example of these colleagues will enforce enthusiasm of others to help organize more courses or “donate” their time to serve as lecturers. We are happy to continue our collaboration with our head of the ESACT secretariat, Dr. António Roldão. He is managing member support, the WEB site, the Newsletter, and a bundle of secretarial work of diverse nature. A major new initiative concerns the support for engagement with, and career progression of, early career scientists into the ESACT sector. The XC is planning a new „institution“, the ESACT FRONTIERS PROGRAMME (EFP). A number of younger individuals shall be selected to form the initial EFP and receive financial and mentoring support from ESACT. The EFP shall start new actions and help to direct the society into the future generations. Under the leadership of XC members Yvonne Genzel and Alan Dickson, and with support from Anne Tolstrup and Stefanos Grammatikos, this new institution within ESACT is in initial stages of establishment. With their help the initial EFP group will be established and become active during 2014 and the fledgling EFP will introduce itself during the next ESACT meeting (Barcelona 2015). We believe that such a group will express the interests of the younger generation and raise new activists for the welfare and the future of the society. IMI2 Brief Follow-up on the ESACT Executive Committee activities regarding the Integrated Medicines Initiative (IMI2) Many scientific ACT projects were supported by EU grants in the 80s and 90s. However, the programs of the commission from the past 10 years did not show explicit funding opportunities in this field. Instead, ACT comes as part of integrated activities. Already during the last ESACT periods, we asked how we can lobby the establishment of new programs. Our industrial platform partner, ACTIP (Animal Cell Technology Platform) has addressed this problem as well and we have directed letters with position papers to the EU Commission requesting better recognition of our work. As a result of these position papers and some lobbying by ACTIP a delegation from ESACT and ACTIP (Chantra Eskes, Luc Kupers, Hansjörg Hauser) was invited to Brussels to discuss the issue with Arnd Hoeveler, Head of Directorate F.4 “Advanced therapies and systems medicine” and his crew. We learned that the Commission recognizes our activity but will continue to look at it as a part of integral projects that are dedicated to, for example, the treatment of certain diseases. Our attention was directed towards IMI (Integrated Medicines Initiative), an initiative by which EC and industry (EFPIA) co-fund large projects. This led to an initiative, in which the above team, with input from both societies could add to the draft of IMI2, a program that is most probably launched in June 2014. While the general goal of this program was almost defined, we could establish a number of elements that match ACT components. We will keep the ESACT community informed and ask you to think about potential projects. ESACT Annual General Assembly According to our constitution a General Assembly (GA)
The cookies we use on Flipsnack's website help us provide a better experience for you, track how our website is used, and show you relevant advertising. If you want to learn more about the cookies we're using, make sure to check our Cookie policy
We use essential cookies to make our site work for you. These allow you to navigate and operate on our website.
We use performance cookies to understand how you interact with our site.They help us understand what content is most valued and how visitors move around the site, helping us improve the service we offer you.
We use marketing cookies to deliver ads we think you'll like.They allow us to measure the effectiveness of the ads that are relevant for you.